Related Experiment Video

Updated: Nov 9, 2025

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.6K

CDC2-like (CLK) protein kinase inhibition as a novel targeted therapeutic strategy in prostate cancer

Simon Uzor1,2, Sean R Porazinski1,3, Ling Li4

  • 1Faculty of Health and Applied Sciences, University of the West of England, Coldharbour Lane, Bristol, BS16 1QY, UK.

Scientific Reports
|April 13, 2021
PubMed

Insights

Targeting CDC2-like kinases (CLKs) with the inhibitor TG003 effectively reduced prostate cancer cell growth, migration, and invasion. This suggests CLK inhibition offers a promising new therapeutic strategy for prostate cancer treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Genetics

Background:

  • Alternative splicing dysregulation is a hallmark of cancer, impacting both its development and progression.
  • CDC2-like kinases (CLKs) are increasingly recognized for their role in cancer pathogenesis.
  • Understanding the impact of CLK inhibition on cancer cells is crucial for developing new therapies.

Purpose of the Study:

  • To investigate the therapeutic potential of the CLK inhibitor TG003 in prostate cancer.
  • To elucidate the effects of TG003 on prostate cancer cell proliferation, apoptosis, migration, and invasion.
  • To analyze the transcriptomic changes induced by TG003, focusing on alternative splicing events.

Main Methods:

  • Treatment of prostate cancer cell lines (PC3, DU145) with TG003.
  • Assessment of cell proliferation, apoptosis, migration, and invasion.
  • Overexpression of CLK1 in PC3 cells to study its effect on TG003 response.
  • Xenograft studies in nude mice using PC3 cells.
  • Transcriptomic analysis of TG003-treated cells.

Main Results:

  • TG003 significantly reduced proliferation and increased apoptosis in PC3 and DU145 cells.
  • Overexpression of CLK1 counteracted the anti-proliferative effects of TG003.
  • TG003 inhibited cell migration, invasion, and xenograft tumor growth.
  • Transcriptomic analysis revealed widespread changes in alternative splicing of cancer-associated genes.

Conclusions:

  • Targeting CLKs with TG003 demonstrates significant anti-cancer effects in prostate cancer models.
  • Inhibition of CLKs represents a novel therapeutic strategy for prostate cancer.
  • Further research into CLK-targeted therapies is warranted for prostate cancer treatment.

More Related Videos

Identification of Novel CK2 Kinase Substrates Using a Versatile Biochemical Approach11:11

Identification of Novel CK2 Kinase Substrates Using a Versatile Biochemical Approach

Published on: February 21, 2019

7.6K
Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

11.2K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.2K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.0K
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
37.2K
Anaphase Promoting Complex00:50

Anaphase Promoting Complex

The stepwise destruction of specific proteins is necessary for the progression and completion of the cell cycle. Such proteins are ubiquitinated by ubiquitin ligases and then subsequently destroyed by the proteasome. The SCF (Skp1/Cullin/F-box) and the anaphase-promoting complex (APC) are two important ubiquitin ligases involved in cell cycle progression. While SCF is active throughout the cell cycle, APC gets activated during metaphase to anaphase transition. Cdc20 or Cdh1 binds to APC and...
3.0K
Positive Regulator Molecules02:39

Positive Regulator Molecules

Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
6.0K